<DOC>
	<DOCNO>NCT00036764</DOCNO>
	<brief_summary>Phase II trial study effectiveness BMS-247550 treating patient stage IV melanoma . Drugs use chemotherapy use different way stop tumor cell divide stop growing die</brief_summary>
	<brief_title>BMS-247550 Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy BMS-247550 patient stage IV melanoma . II . Determine toxicity drug patient . OUTLINE : This multicenter study . Patients stratify accord number prior chemotherapy regimen ( 0 v 1-2 , include dacarbazine temozolomide ) . Patients receive BMS-247550 IV 1 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>Histologically cytologically confirm stage IV melanoma At least 1 measurable lesion Greater 20 mm conventional technique Greater 10 mm spiral CT scan Known brain metastasis allow follow criterion meet : Radiologically stable least 6 week completion whole brain radiotherapy Stable time study No mass effect present radiologically No concurrent steroid control symptoms brain metastasis Performance status ECOG 02 Performance status Karnofsky 60100 % At least 3 month Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST/ALT great 2.5 time upper limit normal ( ULN ) Creatinine great 1.5 time ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior severe allergic reaction ( grade III IV grade II responsive steroid ) taxanes medication contain Cremophor EL No preexist grade 2 great peripheral neuropathy No HIVpositive patient receive combination antiretroviral therapy No concurrent uncontrolled illness No ongoing active infection No psychiatric illness would preclude study Prior vaccine therapy allow Prior immunotherapy ( e.g. , interleukin2 interferon ) allow Stratum I : No prior chemotherapy Stratum II : No 2 prior chemotherapy regimen ( must include dacarbazine temozolomide ) See Disease Characteristics See Disease Characteristics Prior limbperfusion therapy allow ( stratum II ) No concurrent investigational commercial agent therapy intend treat malignancy No concurrent Hypericum perforatum</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>